Assess whether integration costs were sandbagged in the CIM (28b2bf)

Situation

A health-system acquiring a specialty practice cannot treat a founder who will not sign a non-compete as color commentary on related-party revenue that disappears at close. Buy-side QoE lead must close integration costs were sandbagged from that extract under M&A Due Diligence / Legal, IP, and Regulatory.

Decision

Buy-side QoE lead in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using related-party revenue that disappears at close after a founder who will not sign a non-compete.

Hypotheses to test

• A founder who will not sign a non-compete is noise around an already-controlled Legal, IP, and Regulatory process in a health-system acquiring a specialty practice, given related-party revenue that disappears at close.
• A founder who will not sign a non-compete is the event in related-party revenue that disappears at close that forces Proceed for buy-side QoE lead under M&A Due Diligence.
• Related-party revenue that disappears at close shows a one-file miss after a founder who will not sign a non-compete, not a Legal, IP, and Regulatory program failure.
• Related-party revenue that disappears at close cannot decide integration costs were sandbagged yet after a founder who will not sign a non-compete; hold is the only M&A Due Diligence close a health-system acquiring a specialty practice can defend.

Analysis required

• Map reps, earnout mechanics, and integration risk a health-system acquiring a specialty practice would inherit.
• Tie quality-of-earnings, working-capital, and contingent items in related-party revenue that disappears at close to integration costs were sandbagged.
• Name the document buy-side QoE lead still needs before signing.
• For this M&A Due Diligence Legal, IP, and Regulatory file, read related-party revenue that disappears at close against a founder who will not sign a non-compete and write the one fact that would move integration costs were sandbagged for buy-side QoE lead.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (related-party revenue that disappears at close after a founder who will not sign a non-compete). Lead with the M&A Due Diligence option related-party revenue that disappears at close can support after a founder who will not sign a non-compete, then the two facts that force it, then the Monday action for buy-side QoE lead in a health-system acquiring a specialty practice.